tbuckley/cabot-search huggingface dataset:
Successful Harvesting of Peripheral Hematopoietic Stem Cells after Induction Treatment with Bortezomib, Adriamycin, Dexamethasone (PAD) in Patients with Newly Diagnosed Multiple Myeloma (MM)
Authors: Hartmut Goldschmidt, Henk M. Lokhorst, Uta Bertsch, Bronno van der Holt, Laila el Jarari, Hans-Jürgen Salwender, Sonja Zweegman, Edo Vellenga, Jörg Schubert, Igor W. Blau, Asiong Jie, Berna Beverloo, Dirk Hose, Helgi van de Velde, Martyn Ronald Schaafsma, Marie Jose Kersten, Michel Delforge, Okke de Weerdt, Rene Van der Griend, Pierre Wijermans, Hans Martin, Christof Scheid, Mathias Hänel, Ingo G.H. Schmidt-Wolf
Journal: Blood (2008)
Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients
Authors: Pamela Samson, Clifford Robinson, Jeffrey Bradley, A. Craig Lockhart, Varun Puri, Stephen Broderick, Daniel Kreisel, A. Sasha Krupnick, G. Alexander Patterson, Bryan Meyers, Traves Crabtree
Journal: Journal of Thoracic Oncology (2016)
P3-072: Bone Scan Flare Phenomenon in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treated Non-Small-Cell Lung Cancer Patients
Authors: Heng-Sheng Chao, Cheng-Pei Chang, Chao-Hua Chiu, Lee-Shing Chu, Yuh-Min Chen, Reury-Perng Perng, Chun-Ming Tsai
Journal: Journal of Thoracic Oncology (2007)
Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials
Authors: J Valentin Garcia-Gutierrez, Begoña Maestro, Luis Felipe Casado, Manuel Perez-Encinas, Isabel Massague, Raquel De Paz, Santiago Osorio, Joaquin Martinez, Guiomar Bautista, Pilar Giraldo, Carmen Burgaleta, Maria Jesús Peñarrubia, Maria José Requena, Carmen Calle, Jose Angel Hernandez-rivas, Pilar Cano, Juan Luis Steegmann
Journal: Blood (2012)
Enfermedades físicas en pacientes con trastornos mentales graves. 1. Prevalencia, repercusión de los medicamentos y discrepancias en la asistencia sanitaria
Authors: Marc De Hert, CU Correll, J Bobes, M cetkovich-Bakmas, D cohen, I Asais, Johan Detraux, S GaUtam, HJ Möller, DM Detei, J Newcomer, R Uwakwe, S Leucht
Journal: World Psychiatry (2011)
Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study
Authors: Thomas Daikeler, Myriam Labopin, Massimo di Gioia, Mario Abinun, Tobias Alexander, Irene Miniati, Francesca Gualandi, Athanasios Fassas, Thierry Martin, Carl-Philipp Schwarze, Nico Wulffraat, Maya Buch, Antonia Sampol, Enric Carreras, Benedict Dubois, Bernd Gruhn, Tayfun Güngör, David Pohlreich, Annemie Schuerwegh, Emilian Snarsky, John Snowden, Paul Veys, Anders Fasth, Stig Lenhoff, Chiara Messina, Jan Voswinkel, Manuela Badoglio, Jörg Henes, David Launay, Alan Tyndall, Eliane Gluckman, Dominique Farge
Journal: Blood (2010)
Increased systemic stability, tumor accumulation and in vitro and in vivo efficacy of a secretory phospholipase 2-degradable liposomal form of cisplatin.
Authors: Morten Petersen, Fredrik Melander, Jakob Larsen, Mats Leeman, Anders Vikbjerg, Frederik Dagnaes-Hansen, Margit Baeksted, Birgitte Toft, Grete Jacobsen, Caroline Witton, Kent Jorgensen
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

5618 

Cisplatin is one of the most potent antitumor agents known, displaying activity against a large number of solid tumors. However, side-effects such as nephrotoxicity and neurotoxicity as well as cellular resistance to the agent mean that this is not a first choice drug in many cancers. An improved drug delivery system which is expected to reduce these side effects is highly desirable. We have designed a liposomal form of cisplatin (LiplaCis) that can be specifically degraded by secretory phospholipase A2 (sPLA2). sPLA2 is often present in tumor tissues, either expressed by the cancerous cells or by infiltrating immune cells thereby assuring a site-specific release in the tumor micro-environment. The specificity of sPLA2-mediated release was demonstrated in vitro with cells highly resistant to LiplaCis in the absence of sPLA2. In contrast, in the presence of sPLA2 the IC50 values are lower than for free cisplatin which is due to a simultaneous release of lysolipids from the liposomes. In vivo pharmacokinetic experiments in rats and mice show an increased stability in plasma and the effect is present after >14 days. Xenograft studies in nude mice using the mouse mammary carcinoma tumor model MT-3, the mouse colon carcinoma CT-26 or the human colon carcinoma Colo205 revealed long-lasting tumor accumulation of LiplaCis within hours after administration. Efficacy studies using the MT-3 -model showed improved tumor elimination compared to the free drug with similar toxicity. Thus, LiplaCis is expected to perform better than free cisplatin in the clinic and phase one studies will be initiated in early 2008.
Hypermethylation of O6-Methylguanine-DNA Methyltransferase (MGMT) Predicts Response to Laromustine (Cloretazine®) in Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Authors: Ilan Bernstein, Francis Giles, Susan O’Brien, Elizabeth Sullivan, Norbert Vey, Allen S. Yang
Journal: Blood (2008)
P1-082: Metabolic tumor volume predicts disease progression and overall survival in lung cancer
Authors: Billy W. Loo, Percy Lee, Dilani K. Weerasuriya, Philip W. Lavori, Andrew Quon, Peter G. Maxim, Quynh-Thu Le, Heather A. Wakelee, Jessica S. Donington, Edward E. Graves
Journal: Journal of Thoracic Oncology (2007)
P1-078: Lung cancer in patients younger than 40 years of age: imaging characteristics at multidetector row CT
Authors: Kun Young Lim, Soo Hyun Lee, Ji-Youn Han, Heung Tae Kim, Jin Soo Lee, Jae Ill Zo, Geon Kook Lee, Hyae Young Kim
Journal: Journal of Thoracic Oncology (2007)
<sup>18</sup>f-fluorodeoxyglucose-positron emission tomography (FDG-PET) as a predictive biomarker in metastatic colorectal cancer (mCRC).
Authors: S. Gupta, L. K. Heilbrun, D. Smith, A. F. Shields, P. A. Philip
Journal: Journal of Clinical Oncology (2010)

e14120 Background:Information on the prognostic and predictive role of FDG-PET in the management of patients (pts) with mCRC is limited. The growing complexity of current therapies and the increasing number of agents to be tested in this disease warrants better understanding of the role of FDG-PET in earlier treatment decisions. Methods: Consecutive pts with 2 or more serial FDG-PET scans at baseline and during the treatment course were studied. Tumor standardized uptake value (SUV) and its percentage change (%DSUV) were each studied for their potential association with time to progression (TTP) via univariate Cox models to estimate the hazard ratio (HR) for progression. Results: 31 pts (median age 58.4 yrs) with mCRC were studied. 87% of pts were treated in the first line setting. 48% had received prior adjuvant therapy. 61%, 22% and 13% received oxaliplatin based, irinotecan based, and fluropyrimidine only regimens, respectively. 84% received concurrent bevacizumab. Median pretreatment SUV was 9.0 (range 1.7-46.0); median post treatment SUV was 4.0 (range 0 - 13.5); median %DSUV was -70.7 (range -10% to -100%). Median interval between scans was 3.0 months. 9 (29%) patients had no tumor uptake on post treatment scans. 55% and 39% of pts had partial response and stable disease (RECIST criteria), respectively. Median TTP was 11.9 months (90% CI: 9.9–13.7 mos), with a median follow-up time for progression of 15.4 months. The HRs for baseline SUV and %DSUV were 1.009 (90% CI: 0.978–1.040, p = 0.635) and 1.014 (90% CI: 1.002–1.026, p = 0.049), respectively. Among the 20 pts with inter-scan interval < 4 months, the median TTP of pts with posttreatment SUV = 0 was 9.7 months vs. 6.6 months for pts with post-treatment SUV > 0. TTP duration did not differ significantly (p = 0.085). Conclusions: Systemic therapy substantially decreased the SUV on follow up PET scans in pts treated for mCRC. However, no significant association was seen between either baseline SUV or %DSUV and TTP. Further work is needed to optimize and standardize evaluation of tumor response in mCRC patients with FDG- PET. No significant financial relationships to disclose.
Temoporfin-loaded 1-tetradecanol-based thermoresponsive solid lipid nanoparticles for photodynamic therapy
Authors: Ingrid Brezaniova, Martin Hruby, Jarmila Kralova, Vladimir Kral, Zulfiya Cernochova, Peter Cernoch, Miroslav Slouf, Jana Kredatusova, Petr Stepanek
Journal: Journal of Controlled Release (2016)
Clonal hematopoiesis in patients with dyskeratosis congenita
Authors: Nieves Perdigones, Juan C. Perin, Irene Schiano, Peter Nicholas, Jaclyn A. Biegel, Philip J. Mason, Daria V. Babushok, Monica Bessler
Journal: American Journal of Hematology (2016)

Dyskeratosis congenita (DC) is a rare inherited telomeropathy most frequently caused by mutations in a number of genes all thought to be involved in telomere maintenance. The main causes of mortality in DC are bone marrow failure as well as malignancies including leukemias and solid tumors. The clinical picture including the degree of bone marrow failure is highly variable and factors that contribute to this variability are poorly understood. Based on the recent finding of frequent clonal hematopoiesis in related bone marrow failure syndromes, we hypothesized that somatic mutations may also occur in DC and may contribute at least in part to the variability in blood production. To evaluate for the presence of clonal hematopoiesis in DC, we used a combination of X‐inactivation, comparative whole exome sequencing (WES) and single nucleotide polymorphism array (SNP‐A) analyses. We found that clonal hematopoiesis in DC is common, as suggested by skewed X‐inactivation in 8 out of 9 female patients compared to 3 out of 10 controls, and by the finding of acquired copy neutral loss‐of‐heterozygosity on SNP‐A analysis. In addition, 3 out of 6 independent DC patients were found to have acquired somatic changes in their bone marrow by WES, including a somatic reversion in DKC1 , as well as missense mutations in other protein coding genes. Our results indicate that clonal hematopoiesis is a common feature of DC, and suggest that such somatic changes, though commonly expected to indicate malignancy, may lead to improved blood cell production or stem cell survival. Am. J. Hematol. 91:1227–1233, 2016. © 2016 Wiley Periodicals, Inc.
P1-197: Urinary N1,N12-Diacetylspermine(DiAcSpm) as a tumor marker for non-small cell lung cancer
Authors: Koji Sakaguchi, Hirotoshi Horio, Manabu Yamamoto, Kyoko Hiramatsu, Masao Kawakita, Ryosuke Tsuchiya
Journal: Journal of Thoracic Oncology (2007)
Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial.
Authors: Nicolas Penel, Olivier Mir, Antoine Italiano, Jean-Yves Blay, Jennifer Wallet, Francois Bertucci, Christine Chevreau, Sophie Piperno-Neumann, Emmanuelle Bompas, Sebastien Salas, Christophe Perrin, Corinne Delcambre, Bernadette Lieg-Atzwanger, Maud Toulmonde, Thomas Ryckewaert, Isabelle Laure Ray-Coquard, Stephanie Clisant Delaine, Axel Le Cesne, Thomas Brodowicz
Journal: Journal of Clinical Oncology (2016)

11003 Background: We investigated the activity and safety of RE in doxorubicin-pretreated metastatic soft tissue sarcomas (STS). Methods: REGOSARC (NCT01900743) consisted of 4 independent cohorts of patients (pts) who were randomized (1:1) to receive either RE (160 mg/d, 21/28 d) or PL, with optional cross-over. Key-eligibility criteria were age ≥ 18, metastatic sarcoma, ≤ 3 previous lines of treatment for metastatic sarcoma. The primary endpoint was progression-free survival (PFS) with blinded central radiological review. Statistical assumptions were PFS = 1.6 months (mo) with PL, PFS = 4.6 mo with RE, 1-sided α = 0.1 and β = 0.05 (0.2 in SYN cohort). Results: From July 2013 to December 2014, 181 pts previously exposed to doxorubicin (178, 98%), ifosfamide (107, 59%), trabectedin (70, 38%), and pazopanib (6, 3%) were enrolled (89 with RE and 92 with PL; including 70 cross-over). Activity endpoints are displayed in the Table below. Four partial responses have been confirmed in RE arms, one in SYN pts and three in OTH pts (2 angiosarcomas and 1 solitary fibrous tumour). The drug-related maximal toxicity grade distribution by patient with RE (n=89) and PL (n=92) was Grade 5 (1 vs. 0; 1% vs. 0%; hepatitis), Grade 4 (3 vs. 0; 3% vs. 0%), Grade 3 (51 vs. 8; 57 vs. 9%), Grade 2 (18 vs. 22; 20 vs. 24%) and Grade 1 (7 vs. 13; 8 vs. 14%). The most common AEs in RE-treated pts were: asthenia (58, 63%), diarrhea (39, 44%), mucositis (39, 44%), Hand-Foot skin syndrome (39, 44%), anorexia (34, 38%) and arterial hypertension (32, 36%). Conclusions: Excluding LIPO, RE is an active drug providing statistically and clinically significant PFS improvement in pre-treated STS pts. Safety of RE is as expected. Clinical trial information: NCT01900743.Survival outcomes in STS. Cohorts Arm n PFS (mo) HR p OS (mo) HR p LIPO RE 20 1.1 1.13 0.70 4.7 1.57 0.21 LIPO PL 23 1.7 8.8 LMS RE 28 3.7 0.45 0.005 21.0 0.50 0.06 LMS PL 28 1.8 9.1 SYN RE 13 5.6 0.09 < 0.0001 13.4 0.87 0.79 SYN PL 14 1.0 6.7 OTH RE 29 2.9 0.45 0.006 12.1 0.75 0.38 OTH PL 27 1.0 9.5 Non-LIPO RE 70 4.0 0.36 <0.0001 13.4 0.67 0.06 Non-LIPO PL 69 1.0 9.0
Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT
Authors: Silke Heidenreich, Dimitris Ziagkos, Anja van Biezen, Jürgen Finke, Uwe Platzbecker, Dietger Niederwieser, Hermann Einsele, Wolfgang A Bethge, Michael Schleuning, Dietrich W. Beelen, Johanna Tischer, Arnon Nagler, Bertram Glass, Johan Maertens, Carlos Richard, Yves Beguin, Heinz Sill, Theo de Witte, Marie Robin, Nicolaus Kroeger
Journal: Blood (2015)
The Challenge of Developing Autophagy Inhibition as a Therapeutic Strategy
Authors: David A. Gewirtz
Journal: Cancer Research (2016)

The finding that cancer chemotherapeutic drugs and ionizing radiation often promote autophagy has provided the foundation for clinical trials combining autophagy-blocking agents with antitumor drugs and radiation. The premise driving these trials is that therapy-induced autophagy is cytoprotective; consequently, inhibition of autophagy is anticipated to sensitize malignancies to therapy. However, it is well-established that autophagy may also mediate the toxicity of antitumor drugs while evidence also exists for a nonprotective function of autophagy. Consequently, given that it cannot be predicted what form autophagy will take upon treatment with chemotherapy or radiation, the current ongoing clinical trials are likely to generate contradictory or inconsistent results, with the potential consequence that autophagy inhibition could be dismissed as therapeutic strategy based on what are essentially false-negative outcomes. Appropriate interpretation of the outcomes of these trials would require knowledge as to whether the drugs or radiation used promote the cytoprotective form of autophagy in the tumor cells as well as whether the chloroquine or hydroxychloroquine actually inhibit the autophagy. Ultimately, it will be necessary to identify those patients for whom the strategy of autophagy inhibition would be anticipated to improve the response to therapy. However, this is currently not feasible in the absence of appropriate bioassays or predictive markers for characterization of the autophagy or the effectiveness of pharmacologic approaches for autophagy inhibition in the clinic. Cancer Res; 76(19); 5610-4. ©2016 AACR.
P140 Effects of indacaterol/glycopyrronium on lung function and physical activity in patients with moderate to severe COPD: Abstract P140 Table 1
Authors: H Watz, C Mailaender, A-M Kirsten
Journal: Thorax (2015)

<h3>Rationale</h3> Indacaterol/glycopyrronium (IND/GLY, QVA149) is a combination of a long-acting beta-2 agonist and a muscarinic receptor antagonist for the once-daily treatment of COPD. Here we assessed the effects of indacaterol/glycopyrronium on lung function and physical activity compared with placebo. <h3>Methods</h3> We performed a randomised, two-period, cross-over study (21 days of treatment separated by a wash-out period of 14 days) with IND/GLY 110 µg/50 µg or matching placebo. Lung function was measured by slow and forced spirometry. Physical activity was measured by an activity monitor (Bodymedia SenseWear Armband) over the last week of each treatment period. The primary endpoint was peak inspiratory capacity (IC) at the end of each treatment period (i.e., on Day 21). The co-primary endpoint was physical activity level as defined by daily activity-related energy expenditure (kcal/day). Secondary endpoints included number of steps per day, duration of at least moderate activity per day, peak IC and FEV<sub>1</sub> on Day 1, trough IC on Day 1, and trough IC and FEV<sub>1</sub> on Day 21. <h3>Results</h3> 194 patients (mean age 63 years; mean postbronchodilator FEV<sub>1</sub> 61.6% predicted), were randomised; 183 patients completed the study. Peak IC on Day 21 was 0.202 L greater with IND/GLY compared to placebo (p &lt; 0.001; Table 1). In addition, superiority of indacaterol/glycopyrronium over placebo with regard to other parameters of lung function was demonstrated (Table 1). Compared with placebo, indacaterol/glycopyrronium significantly increased the change from baseline in average physical activity level with a difference of 36.7 kcal/day. Further, IND/GLY -treated patients completed significantly more steps per day with a difference between the two treatment groups of 358.0 steps per day (Table 1). <h3>Conclusion</h3> Compared with placebo, IND/GLY improved lung function and physical activity in patients with moderate to severe COPD.
T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant.
Authors: F. Montanari, G. Bhagat, J. M. Zain, V. E. Seshan, C. S. Magid Diefenbach, S. Clark-Garvey, E. McCormick, M. Crook, M. Conroy, O. O'Connor
Journal: Journal of Clinical Oncology (2010)

8056 Background: PTLD represent a serious complication of both solid organ and bone marrow transplant. The majority of PTLD are Epstein-Barr virus (EBV) positive B-cell proliferations, while T-cell m-PTLD are rarely observed. Due to the paucity of patients reported, this rare lymphoma remains a poorly understood disease. Methods: We analyzed the clinical features and prognosis of 9 T-cell m-PTLD (3 peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), 2 cutaneous T-cell lymphoma (CTCL), 2 γ/δ hepatosplenic T-cell lymphoma (HSTCL), 1 adult T-cell leukemia (ATL) and one acute lymphoblastic lymphoma/leukemia case (T-ALL)). To the best of our knowledge, this is the largest series of T-cell m- PTLD to be reported by a single institution. In addition, we compared them to 59 B-cell m-PTLD diagnosed during the same time frame. Results: T-cell m-PTLD showed a shorter survival compared to B-cell m-PTLD (p=0.02). Among T-cell m-PTLD, median survival was 102 days (range 2 days-5 years) with only 2/9 patients alive at last follow-up (22.2%), both CTCL. Of the 7 deceased, 6 died within 9 months from diagnosis. Among B-cell m-PTLD, median survival was 1.5 years (range 1 day to 17 years) with 30/59 patients alive (51%) at last follow-up. The only clinical feature in both groups predictive of outcome was ECOG score (p<0.001). Even after adjusting for ECOG score, T-cell m-PTLD exhibited inferior survival (p=0.01). Age, gender, organ transplanted, ECOG score, stage, LDH and extranodal involvement were not significantly different in the 2 groups. Interval from transplant to PTLD was shorter and incidence of EBV positivity was higher in the B-cell m-PTLD compared to the T-cell m-PTLD (p=0.052 and p=0.001 respectively), but these features were not associated with a different outcome in B-cell m-PTLD (p=0.5 and p=0.6 respectively). Conclusions: these data continue to support the notion that T-cell related malignancies are associated with inferior outcomes compared to B-cell malignancies, save patients with CTCL. No significant financial relationships to disclose.
Blasts Express Phospho-Akt in the Majority of Adult Patients with Acute Lymphocytic Leukemia (ALL).
Authors: Anjali S. Advani, Sarah Gibson, Tao Jin, Ramon Tiu, Giridharan Ramsingh, Matt Kalaycio, Brian Bolwell, Ronald Sobecks, Mikkael Sekeres, Shawnda Sungren, Eric D. Hsi
Journal: Blood (2006)
The role of beta-blockers and ACE inhibitors in the prevention of trastuzumab-related cardiotoxicity.
Authors: J. Munoz, J. Sheqwara, B. Arango, H. Y. Ali, R. Loutfi, D. W. Weaver
Journal: Journal of Clinical Oncology (2010)

555 Background: Trastuzumab, a humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER-2), has been shown to be effective as therapy for breast malignancies that over express HER-2. Cardiotoxicity and a decrease in left ventricular ejection fraction (LVEF) occur in as many as 27% of women treated with trastuzumab. We present our experience regarding the use of beta-blockers or ACE (angiotensin converting enzyme) inhibitors before exposure to trastuzumab correlating its use with the development of cardiotoxicity. Methods: Women (n = 162) with HER2-overexpressing breast cancer who received trastuzumab over a 9-year period were divided into two groups. 39 patients were taking beta-blockers, ACE inhibitors or both due to history of hypertension before starting trastuzumab. 123 patients were not taking beta-blockers or ACE inhibitors before starting trastuzumab. To assess cardiotoxicity, patients were evaluated for LVEF at baseline and every 3 months during therapy with a 10%-15% decrease in LVEF as criteria for cessation of trastuzumab. Results: The patients that were taking beta-blockers or ACE inhibitors before starting trastuzumab were found to be older (59.9 versus 50.8 years, p = 0.001) and had a smaller decrease in LVEF (4.7 versus 10.3, p < 0.001) when compared to the 123 patients that were not taking beta-blockers or ACE inhibitors. There was a 57% decrease in the odds of having delays in the treatment with trastuzumab for those that were taking beta-blockers or ACE inhibitors which, although not statistically significant due to the small sample size, was suggestive of a positive association (p = 0.136). Also there was a 62% decrease in the odds of having a decrease in LVEF for those that are on beta- blockers or ACE inhibitors which was statistically significant (p = 0.03). Conclusions: This hypothesis generating study would encourage the development of a clinical trial to prospectively evaluate the role of beta-blockers and ACE inhibitors in preventing trastuzumab-related cardiotoxicity. Furthermore, repercussions span not only to the continuation of a targeted agent with a compelling oncologic response but also avoiding cardiac, economical and psychological damage. No significant financial relationships to disclose.
Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen–Negative Patients
Authors: Wen-Juei Jeng, Yi-Cheng Chen, I-Shyan Sheen, Chih-Lang Lin, Tsung-Hui Hu, Rong-Nan Chien, Yun-Fan Liaw
Journal: Clinical Gastroenterology and Hepatology (2016)
Pathological alterations involve the entire skin physiological milieu in infantile and early-childhood port-wine stain
Authors: W. Tan, L.R. Zakka, L. Gao, J. Wang, F. Zhou, M.K. Selig, R. Anvari, A. Sukanthanag, G. Wang, M.C. Mihm, J.S. Nelson
Journal: British Journal of Dermatology (2016)

Author(s): Tan, W; Zakka, LR; Gao, L; Wang, J; Zhou, F; Selig, MK; Anvari, R; Sukanthanag, A; Wang, G; Mihm, MC; Nelson, JS